BioAegis Launches Global 600-Patient Phase 2 Trial of rhu-pGSN to Treat ARDS and Advance Inflammation-Modulating Therapies

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...

May 07, 2025 | Wednesday | News
AGC Biologics Joins Hands with South Korea’s Novelty Nobility for Multisite Bispecific Antibody Project

Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...

May 06, 2025 | Tuesday | News
CEO Chris Cargill Marks One-Year Transformation Milestone as Nxera Pharma Reports Strong Q1 2025 Progress

Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...

May 05, 2025 | Monday | Company results
Scorpius Holdings Announces Strategic Update Amid Rising CDMO Demand, Eyes Expansion into Southeast Asia

Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensi...

May 05, 2025 | Monday | News
Chengdu Origen and Vanotech Dose First Patient in Phase 1 Trial of KH658 Gene Therapy for Wet AMD

Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced  the first patient dosed ...

May 05, 2025 | Monday | News
InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new generation...

May 02, 2025 | Friday | News
John Rim Drives Samsung Biologics to KRW 1.3 Trillion Q1 Revenue as Plant 5 and ADC Facility Fuel Global CDMO Expansion

- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...

April 24, 2025 | Thursday | Company results
Biocon Biologics Clears U.S. Path for Interchangeable Aflibercept Biosimilar Yesafili Through Regeneron Settlement

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd announced  a settlement and license agreement...

April 16, 2025 | Wednesday | News
Atelerix Partners with MineBio to Launch Cryo-Free Cell Preservation Technology in China

Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...

April 16, 2025 | Wednesday | News
Lecanemab Becomes First Approved Disease-Modifying Therapy for Early Alzheimer’s in the EU

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...

April 16, 2025 | Wednesday | News
Precision Medicine in Asia: From Genomics to Oncology Impact

    As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...

April 11, 2025 | Friday | Interview
Shilpa Pharma Lifesciences Passes Second Consecutive FDA Inspection with No Observations

Shilpa Medicare announces that Shilpa Pharma Lifesciences – a wholly owned subsidiary – has successfully passed a U.S. Food and Drug Admin...

April 10, 2025 | Thursday | News
China’s Telitacicept Sets New Benchmark in gMG Treatment with Landmark Phase 3 Results

Impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®...

April 09, 2025 | Wednesday | News
Singapore’s NUS Integrates AI and 3D Bioprinting to Transform Personalised Gum Tissue Grafts

Artificial intelligence streamlines the optimisation of bioprinting parameters for oral soft tissue grafts, reducing time and resourc...

April 04, 2025 | Friday | Reports

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close